Can You Take Kava With Blood Thinners? What the Evidence Shows
Can You Take Kava With Blood Thinners? What the Evidence Shows
By Chester Takau · Updated November 2026
Not without checking with your prescriber or pharmacist first. No human trial has measured bleeding in people who take kava with a blood thinner, so nobody can call the combination proven safe or proven dangerous. There are two plausible reasons for caution: kava may slow the liver enzymes that clear some drugs (warfarin in particular), and one lab study found that kavain reduced platelet clumping. Interaction checkers rate the risk anywhere from low to high. If you take warfarin, Eliquis, Xarelto, aspirin or clopidogrel, ask before you drink.

Is kava a blood thinner?
Not in the way warfarin or Eliquis is. Kava is not sold or studied as an anticoagulant. The concern is that it could add to the effect of one. The only direct evidence is a 1997 study in Planta Medica by Gleitz and colleagues, which found that (+)-kavain inhibited human platelet aggregation and thromboxane synthesis in vitro, probably through the COX enzyme. The concentrations used were roughly 71 to 115 µmol/L, tested in a dish, not in people. No one has followed up with a human trial that counts bleeding events.
A KavaForums post argues that kava's COX effect is probably reversible, unlike aspirin's, and so "may be irrelevant" for blood thinning. The same post admits the studies never said whether kavalactones are reversible or irreversible inhibitors. That is an honest summary of where things stand: a plausible mechanism, no settled answer.
Why would kava change how a blood thinner works?
Mostly through enzymes. Memorial Sloan Kettering's kava monograph (updated May 2025) says kava inhibits CYP2E1 in healthy subjects and may inhibit CYP2C9 and CYP2C19 in lab studies, but that "clinical relevance is uncertain." CYP2C9 matters because it is the main pathway that clears S-warfarin, the more active form of the drug. If kava slows that pathway, warfarin could linger and the INR could rise. That is a reasoned inference from the enzyme data, not a result anyone has shown in patients.
The CDC's April 2026 MMWR report on kava poison-center calls makes the same general point, noting that commercial kava products have been linked to drug interactions through cytochrome P450 inhibition. It does not mention bleeding.
There is a third, separate mechanism. MSKCC notes that long-term use or overdose can cause low blood platelets. Fewer platelets plus an anticoagulant is a worse combination than either alone, though this applies to heavy, prolonged use, not an occasional cup.
Which blood thinners matter most, drug by drug?
"Blood thinner" covers two different drug families, and the kava question differs for each. This table is my own side-by-side of the mechanisms in the sources below, not a clinical guide.
| Drug class | Examples | Possible overlap with kava | What is actually known |
|---|---|---|---|
| Vitamin K antagonist | Warfarin | CYP2C9 clears S-warfarin; kava may inhibit it. Narrow dosing window, INR-monitored | Cleveland Clinic lists kava among herbs that interact. ConsumerLab says it may strengthen warfarin by slowing its breakdown. HelloPharmacist rates it moderate and "theoretical"; another checker rates it high |
| Direct oral anticoagulants (DOACs) | Apixaban (Eliquis), rivaroxaban (Xarelto) | Rely more on CYP3A4 and P-gp. MSKCC says kava does not appear to inhibit 3A4 in humans | One checker calls it low risk but still advises asking your anticoagulation clinic. A physician on JustAnswer said kava and Xarelto "do not function in the same manner." Other consumer pages disagree |
| Antiplatelets | Aspirin, clopidogrel (Plavix) | Both act on platelets; kavain inhibited platelet aggregation and probably COX in vitro | Only the 1997 lab study. No human data on bleeding |
Checker ratings come from HelloPharmacist, TruthStack and Hermetica and disagree with each other, which is itself the finding.
How strong is the evidence?
- Lab only: kavain reduces platelet aggregation in vitro (1997).
- Enzyme data, mixed: CYP2E1 inhibition seen in healthy subjects; CYP2C9 and CYP2C19 inhibition seen in vitro, with unclear clinical relevance.
- Reference lists: Cleveland Clinic and ConsumerLab name kava as a warfarin interactor, on the strength of that mechanism.
- Missing: any human trial or published case series tying kava plus an anticoagulant to bleeding, in the sources I found. In the last six months I found no new study or regulatory action on this specific question.
Does the kind of kava make a difference?
Probably, though no study has tested it. The CDC report says US kava products can be 2 to 10 times stronger than traditional drinks, and it counted 3,101 kava exposures at US poison centers from 2000 to 2025, with 43% involving more than one substance. A traditional water-based cup is a very different dose from a concentrated extract or a shot. If enzyme inhibition depends on dose, strength matters, but that link is my reasoning, not a published finding. For background on the traditional preparation, see kava stump vs root, which covers which part of the plant is used.
Kava bars add another variable. Kava and kratom together made up 30% of 2025 poison-center reports. If you are on a blood thinner, stacking two plant products at once makes it harder to know what caused a problem. Kava is also often combined with caffeine, which is a separate interaction question to raise with your pharmacist.

What should you do if you take both?
- Tell the prescriber or pharmacist who manages your blood thinner, and name the specific product. Drug and herb interaction pages list 260+ kava interactions, so this is a routine question for them.
- If you take warfarin, ask whether to have the INR checked when you start or stop kava. Starting or stopping changes the situation either way.
- Stop kava before surgery. MSKCC advises this.
- Watch for unusual bruising, bleeding gums, nosebleeds that will not stop, or dark stools, and get medical help if they appear.
The larger worry in the CDC and FDA material is the liver, not bleeding. That history, starting with the FDA's 2002 liver advisory, is why regulators stay wary.
Common questions
Can you take kava with Xarelto or Eliquis?
The enzyme argument is weaker for these drugs, because they rely more on CYP3A4 and P-gp and MSKCC says kava does not appear to inhibit 3A4 in humans. One checker calls the pairing low risk, and one physician answer said no added blood-thinning risk. Both still point you to a clinician, and nobody has tested it directly.
Does kava affect INR on warfarin?
It might, through CYP2C9, but I found no study that measured INR in kava users. Mainstream references list it as an interactor, so treat it as a real possibility and ask for INR monitoring.
What about aspirin or Plavix?
The overlap here is on platelets, backed only by the 1997 lab study. A prescriber can tell you whether it matters for your dose and history.
Is kava safe with an aneurysm or other bleeding risk?
There is no research answering this. People on KavaForums have asked it, and it is a question for the specialist treating the condition.
Pharmacist Michael's overview of kava's benefits and risks. I couldn't retrieve its transcript, so I can't confirm it covers blood thinners, and I'm not quoting it. Check it before relying on it.
General guidance, not medical advice. I am a writer, not a clinician. If you take any anticoagulant or antiplatelet drug, your prescriber or pharmacist has the final say on kava.
Sources
- CDC MMWR, April 2, 2026: kava exposures reported to US poison centers
- Memorial Sloan Kettering: kava monograph (updated May 23, 2025)
- Gleitz et al., Planta Medica (1997): kavain and platelet aggregation
- NCCIH: kava fact sheet
- Cleveland Clinic: warfarin tablets
- ConsumerLab: warfarin interactions
- Drugs.com: does kava interact with any drugs?
- HelloPharmacist: kava with warfarin
- KavaForums: is kava a blood thinner? (2020, anecdotal)
- JustAnswer: kava kava and Xarelto (single physician answer)
Transparency note: This article was researched and written by Chester Takau with AI assistance for research gathering and drafting. All recommendations reflect the author's own editorial judgment.
Comments